Meeting
2019 ASCO Annual Meeting
Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response.
Authors
Joshua E. Reuss
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Joshua E. Reuss , Kellie Nicole Smith , Valsamo Anagnostou , Jiajia Zhang , Marianna Zahurak , Justina Caushi , Hok Yee Chan , Haidan Guo , Matthew David Hellmann , Drew M. Pardoll , Julie R. Brahmer , Jamie E. Chaft , Patrick M. Forde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02259621
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8524)
DOI
10.1200/JCO.2019.37.15_suppl.8524
Abstract #
8524
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Assessing the predictive value of ctDNA on relapse in patients with resected stage IB-IIIA NSCLC treated with adjuvant chemotherapy plus concomitant atezolizumab followed by atezolizumab: BTCRC LUN 19-396.
First Author: Fatemeh Ardeshir-Larijani
Poster
2022 ASCO Annual Meeting
Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes.
First Author: Adam Luginbuhl
Poster
2022 ASCO Annual Meeting
NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.
First Author: Thomas Lillie
First Author: Paul Kent